Background: The molecular mechanisms underlying cervical cancer require elucidation to identify novel therapeutic targets. Apurinic/apyrimidinic endodeoxyribonuclease 1 (APE1) is a multifunctional apurinic/apyrimidinic (AP) endonuclease that influences the transcription of many cancer-related genes via microRNome regulation. Herein, we examine the role of miR92b-3p (hereinafter miR-92b), whose processing may be regulated by APE1, in cervical cancer progression. Methods: APE1's processing of miR-92b from its pri-miR form was measured by a quantitative reverse transcription polymerase chain reaction (qRT-PCR)-based ratio. APE1's endonuclease activity was measured with AP-site incision assays. APE1-DROSHA interaction was studied with immunofluorescence, confocal and proximity ligation analyses. The miR-92b's targeting of low-density lipoprotein receptor (LDLR) was investigated with luciferase reporter assays. The miR-92b mimics and shRNA-based miR-92b silencing, as well as LDLR overexpression and short interfering RNA (siRNA)-based LDLR silencing, were employed in CaSki and SiHa cervical cancer cells. Cell proliferation and chemosensitivity to paclitaxel and cisplatin were assayed. Cell-cycle progression and apoptosis were assessed by flow cytometry. Tumor growth was studied in a murine xenograft model. Results: APE1's endonuclease activity, via association with the DROSHA-processing complex, is necessary for processing mature miR-92b, thereby regulating expression of miR-92b's direct target LDLR. The miR-92b promotes cell proliferation in vitro and in vivo, promotes cellcycle progression, and reduces apoptosis and chemosensitivity. LDLR silencing recapitulated miR-92b's transformative effects, while LDLR overexpression rescued these effects. Conclusions: APE1 enhances miR-92b processing, thereby suppressing LDLR expression and enhancing cervical carcinoma progression. Our identification of the novel APE1-miR-92b-LDLR axis improves our understanding of the complex pathogenesis of cervical carcinoma and reveals a novel therapeutic strategy for combating this disease.
Introduction
RNA damage induced by missing bases [e.g. by generation of apurinic/apyrimidinic (AP) sites], or by modification of bases (e.g. by oxidative damage), can alter RNA function and is increasingly found to participate in carcinogenesis. 1 For instance, mRNA damaged by oxidation or AP-site formation can interfere with translational accuracy. 1 In the case of microRNAs (miRNAs), oxidation can alter their regulatory activity, thus modifying expression of target genes. 2 Con sequently, degradation of damaged miRNAs in genotoxic environments can have significant repercussions in oncogenesis and for the development of chemoresistance in existing tumors.
Cells regulate the response to DNA damage via various DNA repair pathways. 3 Damaged bases are fixed by base excision repair (BER), which first generates an AP site that is then cleaved by AP endonucleases followed by repair. 4 AP endodeoxyribonuclease 1 (APE1) is a multifunctional AP endonuclease and BER protein that functions as a master regulator of cell fate under genotoxic stress. 5 APE1 also has a role in chemoresistance by controlling expression of the tumor suppression PTEN (phosphatase and tensin homolog) 6, 7 and of MDR1 (multidrug resistance protein 1). 8, 9 The participation of APE1 in RNA processing and gene transcription has also been established. [10] [11] [12] Numerous lines of evidence support a role for APE1 in RNA metabolism, including (a) binding of its N-terminal domain to structured RNA oligonucleotides in vitro, 13 (b) endonuclease cleavage of AP sites on single-stranded RNAs, leading to RNA degradation, 14 and (c) via exoribonuclease and RNA phosphatase activity at the 3´ end. 14 APE1 is the sole enzyme found to date capable of AP site and oxidatively damaged RNA base removal or of 3´-RNA phosphatase activity. 15 Knockdown (KD) of APE1 has been shown to influence the transcription of many genes related to malignant proliferation, invasiveness, and chemoresistance via miRNome regulation. [15] [16] [17] In a recent study on cervical cancer cells, an exhaustive list of miRNAs directly regulated by APE1 during the cellular response to genotoxic treatment and that may specifically mediate resistance to chemotherapy has been recently detailed. 15 Herein, we consider one candidate miRNA, miR92b-3p (hereinafter miR-92b), whose processing may be regulated by APE1. 15 We demonstrate that during genotoxic exposure, the APE1-miR92b-low-density lipoprotein receptor (LDLR) axis mediates cervical cancer cell progression and that targeting this pathway may constitute a novel therapeutic approach to cervical cancer.
Methods

Ethics statement
This research was approved by the Ethics Committee of the First People's Hospital of Yunnan Province (Kunming, China; KHYY20180814). The approval covered both the sample collection and the animal study. Human tissue specimens collected for this study required written informed consent from the donor. The animal procedures were conducted in accordance with the standards set forth in the Guide for the Care and Use of Laboratory Animals [eighth edition, National Institutes of Health (NIH)].
Cell cultures
SiHa, CaSki, and HeLa cervical carcinoma cells were procured from the American Type Culture Collection. Cultures were maintained in DMEM (Dulbecco's modified Eagle's medium; Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) with 10% fetal bovine serum (FBS; Gibco, Thermo Fisher Scientific) and antibiotics [penicillin (100 U/ml); streptomycin (10 μg/m1)]. HeLa clones overexpressing FLAG-tagged APE1 were maintained in the same media [DMEM, 10% FBS, penicillin (100 U/ml); streptomycin (10 μg/ ml)], which additionally contained the selection antibiotics Zeocin™ (100 μg/ml), blasticidin (3 μg/ml), and geneticin (400 μg/ml; Invitrogen, Thermo Fisher Scientific) to preserve clones with APE1 overexpression. Short hairpin RNA (shRNA)-mediated KD of APE1 was induced by the addition of doxycycline (1 μg/ml; SigmaAldrich, St Louis, MO, USA) to the growth media and cultures were maintained for 10 days according to known protocols. 18, 19 Cultures were grown under an atmosphere of 5% CO 2 and a temperature of 37°C, and were routinely assessed for contaminating mycoplasma.
Transient transfection of HeLa cells with short interfering RNA-resistant APE1 mutants and APE1-short interfering RNA
HeLa cells with stable APE1 KD (3 × 10 6 ) were plated and transiently transfected the following day with plasmid DNA (6 µg) employing Lipofectamine ® 2000 transfection reagent (Invitrogen). The FLAG-bearing plasmids encoded either wild type (WT) or mutant APE1, whose mRNA contains mutations that render them resistant to cleavage by APE1-siRNA (short interfering RNA), but which translate into the intended protein sequence. 15 The expressed APE1 were: (1) APE1 WT , (2) APE1 E96A , (3) APE1 C65S , (4) APE1 N Δ 33 , plus, as a control, (5) empty vector. Cells were harvested 24 hours following the transient transfection.
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Transfection of cells for studies of siRNA-mediated KD of APE1 were performed using 100 pmol of siRNA oligonucleotides and DharmaFECT ™ Transfection Reagent (Dharmacon, Lafayette, CO, USA): (1) APE1-targeted 5´-UAC UCC AGU CGU ACC AGA CCU-3´, or (2) scrambled negative control 5´-CCA UGA GGU CAU GGU CUG dTdT-3´. 15 Cells were harvested 72 hours after transient transfection following by purification of RNA.
Inhibitor treatment of HeLa cells
HeLa cultures were incubated over a specified amount of time with a number of APE1 inhibitors: (1) fiduxosin (40 µM), which inhibits APE1's endonuclease activity, 20 (2) inhibitor #3 (20 µM), also an inhibitor of APE1's endonuclease action, 21 and (3) E3330 (100 µM), an inhibitor of the redox activity of APE1. 22, 23 Immunoprecipitation of APE1-bound RNA HeLa cells (1 × 10 7 per dish) overexpressing FLAG-tagged APE1 WT were plated into two 150-mm culture dishes for RNA immunoprecipitation (RIP) experiments, which were performed according to established protocols. 24, 25 Prior to the RIP assay, HeLa cells were rinsed with phosphate-buffered saline (PBS) buffer (two times), trypsinized, detached gently, and collected by centrifugation at low speed (250 × g) for a short duration (5 minutes) at 4°C. The supernatant was siphoned off and the pelleted HeLa cells were gently suspended in buffer (10 ml PBS). Crosslinking was started by formaldehyde (1% v/v, final concentration) at room temperature (RT). After 10 minutes, cross-linking was halted by glycine (125 mM, final concentration) and the HeLa cells were pelleted again. Pellets were rinsed two times with PBS supplemented with protease inhibitors [both a cocktail (1X, Sigma-Aldrich) and the serine protease inhibitor phenylmethylsulfonyl fluoride (PMSF; 0.5 mM)] and sodium fluoride (NaF; 1 mM), sodium orthovanadate (Na 3 VO 4 ; 1 mM), and RNaseOUT™ (0.5 U/ml, Invitrogen). Cells were then pelleted followed by lysis in a 300 μl aliquot of RIP lysis buffer (50 mM TrisHCl buffered at pH 7.4, with 150 mM NaCl, 1 mM EDTA, 1% w/v Triton X-100, supplemented with PMSF and protease cocktail inhibitors qRT-PCR analysis was performed by the ΔΔct (delta-delta threshold cycle) process and expression levels were normalized to GAPDH and RNU44 for pri-miRNA and miRNA, respectively.
Quantification of RNA containing AP sites
Oxidatively depurinated/depyrimidinated RNA was ARP-labeled and isolated with streptavidin magnetic beads as previously described. 26 Briefly, the Xenopus elongation factor 1α (xEF-1α) control mRNA was added to total isolated RNA to achieve a total of 30 µg RNA. 
Western blot analysis and protein quantification
Cell cultures were rinsed with PBS buffer (two times), trypsinized, detached gently, and collected by centrifugation at low speed (250 × g ) for a short duration (5 minutes) in the cold (4°C). The supernatant was siphoned off and the pelleted cells were gently rinsed in cold PBS, pelleted again by centrifugation, and lysed in buffer on ice for 30 minutes (lysis buffer was 50 mM Tris-HCl buffered at pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM NaF, 1 mM Na 3 VO 4 , 1% w/v Triton X-100, containing protease inhibitors (1X cocktail, 0.5 mM PMSF 27 The assay, and subsequent imaging by confocal microscopy, was performed according to the supplier's directions and established protocols. 25, 28 Briefly, HeLa cells were incubated with hydrogen peroxide (H 2 O 2 , 1 mM) for a duration of 15, 30, and 60 min on coverslips. Then, cells were permeabilized for 10 min with PBS + Triton X-100 0.4%. After two PBS washes, cells were incubated for 30 min with blocking solution (37°C). Then, HeLa cells were serially treated with primary antibodies against: (1) APE1 (1:22, mouse, monoclonal, clone 13B8E5C2, catalog no. NB100-116, Novus Biologicals, Littleton, CO, USA) for 3 hours (37°C), followed by an antibody against (2) DROSHA (1:200, rabbit, polyclonal, catalog no. ab85027, Abcam, Cambridge, UK) overnight (37°C). The cover slips were washed two times with buffer A. The slips were then incubated with PLA probes in antibody diluent for 1 hour (37°C). 
APE1 endonuclease activity by abasic site incision assay
The endonuclease action of APE1 was measured in HeLa cell lysates by tracking abasic site incision according to established protocols. 18, 20 The assay relies on a substrate, which is a doublestranded DNA 26-mer, that contains at position 14 one tetrahydrofuranyl unit that simulates an abasic site. 20 Endonuclease action by APE results in substrate cleavage and the generation of a 14-mer fragment, which is detected on a gel. HeLa cell lysates were prepared to a volume of 10 µl containing 12. 
Generation and stable infection of LDLR overexpression plasmid
The plasmid to induce overexpression of LDLR was generated within a lentiviral vector (pEZLv105, GeneCopoeia, Rockville, MD, USA). The complete LDLR cDNA sequence was cloned into pEZ-Lv105 to generate the LDLR overexpression plasmid. The plasmid sequence was confirmed by DNA sequencing. pEZ-Lv105 lentiviral vectors were packaged into lentiviruses, which were employed to infect cell cultures to create stable lines according to established protocols. 29 Generation and stable infection of anti-miR-92b small hairpin RNA plasmids Plasmids carrying anti-miR-92b small hairpin RNA (shRNA; sh-miR-92b) or scrambled negative control shRNA were generated within a lentiviral vector (pGreenPuro, System Biosciences, Palo Alto, CA, USA). 30 Plasmids were confirmed by DNA sequencing. The pGreenPuro lentiviral vectors were packaged into lentiviruses, which were employed to infect cell cultures to create stable lines according to established protocols. 29 
Transient transfection with siRNAs or mimics
The siRNAs against LDLR (si-LDLR) or scrambled negative control siRNA were generated by GenePharma. Cells were transiently transfected with siRNAs (20 nM) utilizing RNAi-mate Transfection Reagent (GenePharma, Shanghai, China). In addition, miR-92b mimics or scrambled negative control mimics were generated by GenePharma. Cells were transiently transfected with mimics (20 nM) utilizing Lipofectamine ® 2000 transfection reagent (Invitrogen). 
Flow cytometric analysis of cell-cycle progression in SiHa and CaSki cells
Plated SiHa and CaSki cultures underwent transfection (vide supra) After 24 hours, cells were incubated for 16 to 20 hours in media supplemented with nocodazole (100 ng/ml). 30 SiHa and CaSki cells were harvested, fixed in ethanol (70%; −20°C, 24 hours), and incubated with PI (50 μg/ ml, Kaiji). Data analysis was performed on a flow cytometer with the ModFit program (BD Biosciences).
Analysis of caspase-3/7 activation in SiHa and CaSki cells
SiHa and CaSki cells were deposited to 96-well plates at 4000 cells/well for overnight incubation. The growth media was exchanged for serum-free media, and cells were incubated for 24 hours. Caspase-3/-7 activation was quantified using Promega's Caspase-Glo ® assay kit and expressed as the change in readout upon treatment (relative to vehicle) over the average luminescence readout of control wells.
Tumor xenograft grown in vivo in nude mice
Nude mice, aged 5 to 6 weeks, female, were procured from the National Rodent Laboratory Animal Resources (Shanghai, China). The mice were given four days to adapt to their new surroundings. At this point, CaSki cells (4.0 × 10 6 cells) with stable shRNA-mediated KD of miR92b or scrambled negative controls (n = 9 per cohort) were implanted into the groin (right side) of each animal. The increase in tumor mass was registered in grams. Animals were sacrificed 28 days after implantation. 
Results
APE1 binds precursor miR-92b forms
Our study sought to uncover the mechanism of miRNA regulation by APE1, centering our efforts on miR-92b that has been shown to be upregulated upon genotoxic stress but downregulated following APE1 KD. 15 APE1 is known to directly interact with structured RNA oligonucleotides, 10,11 so we surmised it could interact with the double-stranded, primary transcript primiR-17~92 (hereinafter pri-miRNA-92b). 33 To assess this hypothesis, we conducted RIP on a human cervical (HeLa) cancer cell line transiently transfected with WT APE1 with a FLAG tag. By qRT-PCR, the levels of pri-miR-92b that immunoprecipitated with APE1 were significantly increased for all three cancer cell lines (i.e. HeLa, HCT116, and MCF7) examined [ Figure 1(a) ].
Due to APE1's ability to cleave structured RNA, 10, 11 we hypothesized a possible function of APE1 in the processing of miR-92b. HeLa clones were transiently transfected with small interfering RNA (siRNA)-mediated KD of APE1 [ Figure  1 Figure  1) . Cumulatively, these findings imply that miR92b levels and processing of pri-miR-92b are altered in cells with APE1 KD.
Mature miR-92b levels decrease upon inhibition of APE1
Since APE1 is a multifunctional enzyme with both endonuclease and redox activities, 15 we set out to determine which was responsible for processing pri-miR-92b. HeLa cells were treated with distinct inhibitors of APE1's activities: (a) fiduxosin, an inhibitor of the interaction of APE1 with nucleophosmin (NPM1), 34 which localizes APE1 to the nucleus and activates BER, 35 (b) compound #3, an inhibitor of the endonuclease activity of APE1 through a mechanism distinct to fiduxosin, 34, 36 and (c) E3330, an inhibitor of the redox activity of APE1. 37, 38 HeLa cells were exposed to each APE1 inhibitor for 24 h, and both precursor (pri-miR-92b) and mature miR92b forms were measured by qRT-PCR [ Figure  2 (a)]. Dosage and duration of treatment with inhibitors were selected according to their influence on the viability of cancer cells. 34, 39 Inhibiting the endonuclease action of APE1 by fiduxosin and compound #3, which was assayed by cleavage of a substrate with an abasic site in vitro, induced an increase in pri-miR-92b [ Figure  2 (a-c) and Supplementary Figure 2 To corroborate our findings from the experiments employing fiduxosin, compound #3, and E3330 APE1 inhibitors, we transfected HeLa cells with APE1 KD of mutant versions of APE1: (a) APE1 with mutation to E96A (APE1E96A) devoid of nuclease activity, 40 (b) APE1 with mutation to C65S (APE1C65S) devoid of redox activity, 41 and (c) APE1 without the 33 N-terminal amino acids (APE1N-33) devoid of binding to NMP. 5, 12, 42 All mutant APE1 levels were similar in these cells whose native, WT APE1 levels were very low [ Figure 2 , and attribute the endonuclease activity and N-terminal domain of APE1 as necessary features to correctly process pri-miR92b. On the other hand, expression of APE1C65S, which is devoid of redox activity, induced a marginal elevation in mature miR-92b levels, attributable to secondary effects from overexpressing it in cells, as reported in the literature. 43 Furthermore, due to the dual function of the 33 residue N-terminal domain of APE1 that provides both localization cues and interacts with proteins other than NPM1, 16 we cannot eliminate the possibility that the effect of APE1N-33 on primiR-92b processing derives from loss of either of these functions. 34 and suggest that NPM1 positively influences APE1 in its role in the processing of pri-miRNAs.
Finally, since we observed that APE1 KD decreased pri-miR-92b processing, we determined whether overexpression (OE) of APE1 could exert an adverse result [ Figure 2(g-i) ]. Consequently, a vector of APE1 with a FLAG tag was transfected into HeLa cells, but resulted in no significant change to the miR/pri-miR ratio. The lack of any discernible effect could arise from other proteins involved in pri-miR-92b processing, which could limit the processing rate. Cumulatively, our findings demonstrate that the endoribonuclease property of APE1 may be essential in the early stages of miR-92b processing; however, contributions from other proteins may factor in.
Genotoxic stress augments the interaction between APE1 and DROSHA Since APE1 KD induces a greater extent of RNA oxidation, 12 we hypothesized that the dependency in the processing of pri-miR-92b on APE1 could arise from the influence of the DROSHA microprocessor complex on APE1. Indeed, previous research has demonstrated that APE1, through interacting with the DROSHA microprocessor complex, can promote miR maturity. 15 As oxidative stress promotes the APE1/DROSHA interaction, 15 an interaction between DROSHA and APE1 was induced upon addition of hydrogen peroxide (H 2 O 2 , 1 mM), which maximized after 15 minutes [ Supplementary Figure 3(a, b) ], and suggested an involvement by APE1 in the degradation of oxidatively damaged RNA. 44 Hydrogen peroxide induced elevation in the level of pri-miR-92b within 15 minutes compared to untreated cells [NT; Supplementary Figure 3(c, d) ], but did not affect the level of the mature miR-92b strand as evidenced by the kinetic studies of the ratio of miR-92b-to-pri-miR-92b. This situation could arise due to inhibition of pri-miR-92b maturation from H 2 O 2 -induced oxidative stress [ Supplementary Figure 3(c, d) ].
To gain further evidence, we employed a probe with an aldehyde-reactive group (ARP) to quantify the loss of oxidatively damaged bases from pri-miRNAs upon expression of APE1. 26 APE1 KD induced a hike in the extent of oxidative damage on pri-miR-92b, which was reversed upon coexpression of WT APE1 [Supplementary Figure  3(e) ]. These results validate APE1's role in primiR-92b degradation, thereby impacting maturation of miR-92b in a genotoxic environment.
miR-92b directly suppresses LDLR expression in human cervical carcinoma cells
miRNAs function by binding to and regulating the transcription of their mRNA targets. 45 Consequently, to clarify the role of miR-92b in cervical cancer, we set out to uncover its potential target genes. We queried the miRanda (microrna. org and miRbase), TargetScan 
APE1 impacts the LDLR-PTEN pathway and corresponds to miR-92b levels
We next evaluated the functional applicability of our APE1/miR-92b-based experimental results Figure 3(b) ], which were both increased with a simultaneous decrease in the ratio of miR-92b-to-pri-miR-92b. We also assessed the levels of PTEN and Akt phosphorylation, since LDLR negatively impacts the Akt signaling pathway via PTEN upregulation. 46 As anticipated, HeLa cells with APE1 KD displayed raised LDLR, elevated PTEN, and lowered Akt phosphorylation [ Figure 3(c, d) ], while APE1 overexpression (OE) rescued these effects.
We next assessed the comparative expression of APE1 mRNA, miR-92b, and LDLR mRNA levels in human cervical cancer tumor biopsy samples (n = 50) relative to matching healthy cervical tissue (n = 50). We found significantly higher levels of miR-92b in cervical tumors relative to matched healthy cervical tissue (Supplementary Figure 5) . However, we did not discover significant differences in APE1 mRNA expression or LDLR mRNA expression (Supplementary Figure 5) .
We next assessed the interrelationship between APE1 and miR-92b processing to LDLR protein levels in human cervical cancer tumor biopsy samples (n = 50). Immunohistochemistry (IHC) was used to determine LDLR and APE1 protein levels, which were semi-quantitatively scored [0, 1, 2, or 3; Figure 3(e) ]. An inverse correlation emerged between high LDLR protein levels in cervical cancer biopsy samples to low APE1 protein levels [ Figure 3 (f)]. qRT-PCR was employed to quantify mature and primary miR-92b levels and their ratios. Another relationship emerged between greater miR-to-pri-miR ratios (more miR-92b processing) and higher APE1 protein levels [ Figure 3(g) ]. The results in cervical cancer biopsies corroborate the findings in HeLa cells in vitro, namely that APE1's miR-92b processing negatively correlates with LDLR protein levels.
miR-92b increases the proliferation of human cervical carcinoma cells in vitro and in xenograft tumors in vivo
We hypothesized that miR-92b could impact cellular proliferation of cervical cancer cells since its expression levels have an inverse relationship with the tumor-suppressive LDLR-PTEN pathway. 46 We employed two human cervical carcinoma Overall, LDLR KD enhanced cellular proliferation, promoted cell-cycle progression, reduced apoptosis, and reduced chemosensitivity, features common to the influence of miR-92b mimics in human cervical cancer cells.
OE of LDLR mitigates the influence of miR-92b on proliferation and apoptosis
We hypothesized that, as LDLR is a functional target of miR-92b, OE of LDLR would rescue the impact of miR-92b mimics on proliferation and apoptosis of cervical cancer cells. To shed light on the hypothesis, lentiviral constructs containing the LDLR sequence with WT or mutant LDLR 3'-UTRs (LDLR-WT and LDLR-mut, respectively) were infected into CaSki and SiHa cells. These cells were also transfected with miR-92b mimics. As anticipated, cells with miR92b mimics and OE of LDLR-WT displayed decreased cervical cancer cell proliferation [ Figure 5 (k, l)], enhanced G1 phase arrest [ Figure 5 (m, n)], and promoted apoptosis [ Figure 5 (o, p)]. Notably, these effects were not observed in cells with miR-92b mimics and OE of LDLR-mut. Cumulatively, these experiments illustrate that OE of WT LDLR reverses the promalignant impact of miR-92b mimics on cellular proliferation, cell-cycle progression, and apoptosis in cervical cancer cells. These findings advocate LDLR as a functional intermediary of miR-92b.
Discussion
Here, we reveal that the BER endonuclease APE1, via interacting with the DROSHA microprocessor complex, enhances miR-92b maturity, thereby suppressing LDLR-PTEN pathway expression and upregulating Akt activation under baseline conditions. As oxidative stress enhances the APE1-DROSHA interaction and APE1 KD promotes oxidized pri-miR-92b levels, our findings also validate APE1's role in regulating degradation of primary miRNA transcripts. Noting that APE1's endoribonuclease activity affects many oxidized and abasic miRNA species, 12 our findings may be generalized to other oxidative stress-regulated miRNAs which are also subject to oxidative, alkylative, or abasic damage. 48 As APE1 appears to preferentially target the primiRNA duplexes of these oxidative stress-regulated miRNA species 17, APE1's role in regulating responses to genotoxicity and in carcinogenesis should be closely investigated.
miR-92b is a product of the polycistronic miR-17~92 cluster situated on chromosome 13, whose aberrant overexpression is present in several cancers. [49] [50] [51] [52] [53] miR-92b has been shown to target several anticancer genes, including the tumor and metastasis suppressor RECK, 54 the tumor suppressor DKK3, 55 and the epithelial-mesenchymal transition (EMT) suppressor DAB2IP. 56 More importantly, miR-92b promotes cell proliferation, invasiveness, and chemoresistance in various cancer cell types via target gene suppression. [54] [55] [56] [57] Thus, rescuing anticancer gene expression via miR-92b suppression may be a promising therapeutic strategy against many malignancies. As APE1 promotes miR-92b maturation, the application of APE1 inhibitors may represent a novel adjuvant approach to bolster chemotherapeutic efficacy in certain chemoresistant tumors.
Herein, our results reveal that miR-92b suppresses human cervical carcinoma growth in vitro and in vivo via LDLR suppression. LDLR is best-known for its role in maintaining proper cholesterol homeostasis, thereby reducing proatherosclerotic foam cell development. 58 Notably, LDLR also upregulates PTEN, a potent tumor suppressor that suppresses the prosurvival Akt pathway. 46 Therefore, miR-92b-mediated LDLR-PTEN pathway downregulation produces Akt pathway activation, which has been shown to participate in the transformation and chemoresistance of cervical cells. 59, 60 These findings are consistent with previous work showing that APE1 KD upregulates PTEN expression via suppressing miR-221/22 maturation. 15 On the basis of this combined evidence, we propose a regulatory model where APE1 negatively regulates the tumor-suppressive LDLR-PTEN pathway on two levels: via post-transcriptional regulation of LDLR expression by miR-92b and PTEN expression by miR-221/22. Further research is needed to see if this multi-tier regulatory model can be carried over to other cancer cell signaling pathways that are subject to APE1 regulation.
It should be noted that we identified LDLR as one miR-92b target that suppresses the proliferation and cell-cycle progression while promoting apoptosis and chemosensitivity in cervical carcinoma cells. However, based on our analysis of the miRNA databases, other tumor suppressor genes could also be targets of miR-92b. Further research is needed to identify other gene targets that may be involved in miR-92b-mediated cervical carcinoma progression.
We also observed increased chemosensitivity to cisplatin and paclitaxel in miR-92b-silenced CaSki cells and decreased chemosensitivity to cisplatin and paclitaxel in LDLR-silenced CaSki cells. Moreover, we also observed that miR92b-silenced SiHa cells responded differently to cisplatin and paclitaxel, showing no significant chemosensitivity to cisplatin and a less profound chemosensitivity to paclitaxel. This evidence suggests that the APE1-miR-92b-LDLR axis may be involved in regulating chemosensitivity to cisplatin and paclitaxel in cervical carcinoma cells, albeit in varying degrees depending on the particular cell line. Interestingly, preliminary transomics data from epithelial ovarian carcinoma cells suggests that LDLR promotes cisplatin chemosensitivity via the LDLR-lysophosphotidylcholine (LPC)-family with sequence similarity 83-member B (FAM83B)-fibroblast growth factor receptors axis. 61 However, we did not investigate the mechanism underlying this phenomenon in cervical carcinoma cells. Further research is needed to investigate the mechanism(s) that may be involved in APE1-miR-92b-LDLR-mediated chemosensitivity to cisplatin and paclitaxel in cervical carcinoma cells.
Conclusion
APE1 enhances miR-92b processing, thereby suppressing LDLR expression and enhancing cervical carcinoma progression. Our identification of the novel APE1-miR-92b-LDLR axis improves our understanding of the complex pathogenesis of cervical carcinoma and reveals a novel therapeutic strategy for combating this disease.
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